Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Panel Clears Way For Generic ViroPharma Drug

By Pharmaceutical Processing | August 5, 2009

WASHINGTON (AP) — Federal health advisers say generic drug companies should not have to conduct costly human trials before launching generic versions of ViroPharma’s lead drug Vancocin, dealing a major setback to the company’s gastrointestinal infection treatment. An FDA panel of experts has voted unanimously, 16 to 0, that generic drug companies can conduct laboratory tests of their drugs instead of more expensive clinical tests, according to a company spokesman. The FDA is not required to follow the advice of its panels, though it usually does. Vancocin accounts for the vast majority of Viropharma’s revenue, which last year totaled $232 million. The drug is the only FDA-approved therapy for antibiotic-associated gastrointestinal infection. The company’s only other product is a treatment for acute hereditary angioedema, which causes swelling of the face. On Tuesday, ViroPharma executives argued that generic drug companies seeking approval to market Vancocin knockoffs should be required to conduct testing in patients with actual gastrointestinal infections. The panel wasn’t swayed by that argument, however, and sided with FDA’s position that labaratory tests could be used in place of human testing. The agency is expected to make a final ruling later this year, paving the way for low-cost generic versions of Vancocin from Akorn Inc. and other drugmakers.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE